Osteoporosis is a bone disorder in which bone tissue is broken down at an increased rate or is not being built up sufficiently. This leads to a reduction in bone density, resulting in a higher incidence of fractures, some of which can cause permanent functional impairment. It primarily affects older people and postmenopausal women.
The pharmacological treatment of women with post-menopausal osteoporosis involves, amongst other things, medicines that prevent bone resorption (these include bisphosphonates such as risedronate and monoclonal antibodies such as denosumab), and medicines that stimulate new bone formation (including teriparatide).
To determine which of these treatment options is best from the patients’ perspective, the Institute for Quality and Efficiency in Health Care (IQWiG) carried out a comparative benefit assessment of these medicines.
At the time of the review, the following bisphosphonates were available for the treatment of postmenopausal osteoporosis: alendronate, ibandronate, risedronate and zoledronate. The manufacturer of risedronate provided only incomplete data. Consequently, no assessment was carried out for this substance, as the potential for bias was deemed too high. An exception to this is the derivation of an indication of lower benefit from the comparison with teriparatide, as all studies were available for this comparison.
The researchers were able to identify eleven studies that provided sufficient information to assess the similarity of these medicines. However, the studies were insufficient to form a coherent network analysis. Individual comparisons were therefore carried out for the benefit assessment. Criticism was levelled, however, at the availability of data on patient-relevant endpoints, particularly for the following parameters: ‘pain’, ‘functional impairment’, ‘health-related quality of life’, ‘bone necrosis in the jaw’ and ‘symptomatic atypical femoral fractures’. Furthermore, many studies lasted less than two years.
Comparison of denosumab versus bisphosphonates
When comparing the monoclonal antibody denosumab with bisphosphonates, the available data allow reliable conclusions to be drawn only in relation to the active substance zoledronate. In its overall assessment, IQWiG finds no evidence across all endpoints of greater or lesser benefit or harm for either of the two active substances.
Comparison of teriparatide versus risedronate
For teriparatide, IQWiG concludes from the overall assessment across all endpoints that there is evidence of greater benefit compared with risedronate. This is because: for the endpoint ‘symptomatic vertebral fractures’, there was a large effect in favour of teriparatide, whereas the disadvantage for the endpoint ‘adverse gastrointestinal events’ was only minor.
Comparison of bisphosphonates with
one another When comparing bisphosphonates with one another, reliable conclusions can only be drawn for the active substances alendronate and ibandronate on the basis of the available data. Across all endpoints, the overall balance of benefits and harms shows no evidence of greater or lesser benefit or harm for either active substance.
Reference:
IQWiG
press release: Postmenopausal osteoporosis: Benefits of teriparatide compared with risedronate, preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab; 2 June 2022; https://www.iqwig.de/presse/pressemitteilungen/pressemitteilungen-detailseite_70912.html